The CRUK Convergence Science Centre is a partnership between Imperial College London and The Institute of Cancer Research (ICR). We bring together researchers across these institutions from different disciplines to develop innovative ways to address challenges in cancer research and improve patient outcomes.
New Publication: New potential drug for treatment resistant prostate cancer
Through the support of the Centre, a new drug, known as NXP800, has been identified by researchers at the ICR as a potential treatment for hard-to-treat prostate cancers that are resistant to hormone therapy. This research shows how bridging clinical observations and discovery research through convergence science can rapidly offer new treatment options for hard-to-treat cancers.
New Publication: Anticipating treatment resistance in advanced prostate cancer
Olaparib, a PARP inhibitor, offers significant promise for patients with advanced prostate cancer carrying mutations in DNA repair genes. However, resistance to the treatment has been observed, and the common mechanisms driving this resistance remained unclear. A new study from scientists at the Institute of Cancer Research sheds light on how this resistance develops and how these mechanisms can be accounted for in treatment planning.
Registration now open for 2025 CRUK Convergence Science Centre Annual Symposium
Registration is now open for our 2025 annual symposium. Email icr-imperial-convergence.centre@imperial.ac.uk for more information and to receive the registration link.